Incyte Corp
INCY · Healthcare · Biotechnology
Updated 26 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #386 of 500 by Iconic Score · #45 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Incyte Corporation (INCY) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for oncology and other serious diseases. With a market capitalization of $23.5 billion, Incyte has established a strong position in the biotechnology sector, particularly known for its flagship product, Jakafi, which is approved for the treatment of certain blood cancers. The company continues to expand its pipeline with promising candidates targeting various malignancies and autoimmune disorders. Incyte's commitment to advancing precision medicine and addressing unmet medical needs underscores its significance in the healthcare landscape, as it contributes to the evolving field of targeted therapies and personalized treatment options.
IconicOracleAI™ Brief
Incyte Corp's Iconic Score of 37 reflects a moderate brand presence, influenced by its recent participation in key oncology discussions at the ESMO Congress. Despite a strong brand-visibility signal of 85/100, the company's stock price has seen a decline of 2.72%, indicating mixed market sentiment. The broader context includes competitive dynamics in the oncology space and shifts in investor focus, as highlighted by recent headlines regarding other companies in the sector.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.